

KAMUZU UNIVERSITY OF HEALTH SCIENCES

FINANCIAL STATEMENTS

FOR THE YEAR ENDED
31 MARCH 2022
(9 MONTHS)

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

TABLE OF CONTENTS	PAGE
Statement of Council Members' Responsibilities	0
Auditor General's Report	1-3
Statement of Financial Position	4
Statement of Comprehensive Income	5
Statement of Changes in Funds	6
Statement of Cash Flows	7
Notes to the Financial Statements	8-39

STATEMENT OF COUNCIL MEMBERS' RESPONSIBLITIES

The Kamuzu University of Health Sciences Act; requires Members of the Council to prepare financial statements for each year, which give a true and fair view of the state of the financial position of Kamuzu University of Health Sciences as at the end of the financial year and of the results for that year.

The Act also requires Members of the Council to ensure that the University keeps proper accounting records which disclose with reasonable accuracy at any time the financial position of the University and enable them to ensure that the financial statements comply with relevant legislation.

In preparing the financial statements, the Members of the Council accept responsibility for the following: -

- Maintenance of proper accounting records;
- Selection of suitable accounting policies and applying them consistently;
- Making judgement and estimates that are reasonable and prudent;
- Compliance with applicable accounting standards, when preparing financial statements, subject to any material departures being disclosed and explained in the financial statements; and
- Preparation of financial statements on a going concern basis unless it is inappropriate to presume that the University will continue in business.

Members of the Council also accept responsibility for taking such steps as are reasonably open to them to safeguard the assets of the college and to maintain adequate systems of internal control to prevent and detect fraud and other irregularities.

Members of the Council are of the opinion that the financial statements present fairly, in all material respects, the financial affairs of the University and its operating results.

My

VICE CHANCELLOR

DATE 12 May 2023

CHAIRMAN OF COUNCIL

DATE 15.05-35

Telephone: +265 1 770 700 Facsimile: +265 1 773 071

+265 1 776 125 +265 1 774 138

NATIONAL AUDIT OFFICE P.O. BOX 30045 CAPITAL CITY LILONGWE 3 MALAWI

All Communications should be addressed to:
National Audit Office

AUDITOR GENERAL'S REPORT

TO THE COUNCIL OF KAMUZU UNIVERSITY OF HEALTH SCIENCES ON THE FINANCIAL STATEMENTS FOR THE YEAR ENDED $31^{\rm ST}$ MARCH, 2022 (9 MONTHS)

Opinion

I have audited the accompanying consolidated financial statements of Kamuzu University of Health Sciences which comprise the Statement of Financial Position, Statement of Comprehensive Income and Expenditure and the as at 31st March, 2022, Statement of Changes in Funds and Statement of Cash Flows for the year then ended as set out on pages 4 to 7, and related accounting policies and notes to the accounts presented on pages 8 to 39.

In my opinion, the financial statements present fairly, in all material respects, the financial position of the Kamuzu University Of Health Sciences as at 31st March 2022 and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards and best public sector accounting practice.

Basis for Opinion

I conducted my audit in accordance with International Standards of Supreme Audit Institutions (ISSAIs). My responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of my report. I am independent of the Kamuzu University Of Health Sciences in accordance with the International Standards of Supreme Audit Institutions 30- *Code of ethics* (ISSAI 30) as promulgated by the International Organisation of Supreme Audit Institutions (INTOSAI), and I have fulfilled my other ethical responsibilities in accordance with these requirements. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Emphasis of matter

While not modifying my report, I draw your attention to the following matter which has been a major concern during the audit of the Financial Statements of Kamuzu University of Health Sciences

The service gratuity liability amounting to K7.7 billion presented in the financial statements is an area of major concern for me as the University's affordability to meet this huge liability with its current cash flow is doubtful.

Key Audit Matters

Key audit matters are those matters that, in my professional judgment, were of most significance in my audit of the Annual Appropriation Accounts of the current period. These matters were addressed in the context of my audit of the Financial Statements as a whole, and in forming my opinion thereon, and I do not provide a separate opinion on these matters.

I have determined that there are no key audit matters to communicate in my report.

The Council Members' Responsibility for the Financial Statements

The Council is responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Report Standards (IFRS), Donor terms of agreement and financial provisions and for such internal controls as they determine are necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. This responsibility includes designing, implementing and maintaining internal controls relevant to the preparation of the financial statements that are free from material misstatements, whether due to fraud or error.

Auditor's Responsibilities for the Audit of the Kamuzu University of Health Sciences

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards of Supreme Audit Institutions (ISSAIs) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Kamuzu University of Health Science's Financial Statements.

As part of an audit in accordance with ISSAIs, I exercise professional judgment and maintain professional scepticism throughout the audit. I also:

Identify and assess the risks of material misstatement of the financial statements, whether
due to fraud or error, design and perform audit procedures responsive to those risks, and
obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion.
The risk of not detecting a material misstatement resulting from fraud is higher than for one

resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

I also provide those charged with governance with a statement that I have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on my independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, I determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. I describe these matters in my auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances,

I determine that a matter should not be communicated in my report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement auditor on the audit resulting in this independent Auditor General's report is:

THE AUDITOR GEN
NATIONAL AUDIT

THOMAS K B MAKIWA
ACTING AUDITOR GENERAL
NATIONAL AUDIT OFFICE GWE
LILONGWE
MALAWI

DATE: 26 MA> 2023

STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2022

	Note	2022 '9 months'	2021
		MK'000	MK'000
ASSETS			
Non-current assets			
Property, plant and equipment	14	42,712,085	42,494,905
Current assets			
Inventories	15	159,416	33,474
Receivables	16	7,404,652	7,159,779
Cash and cash equivalents	17	11,125,657	7,794,019
Total current assets		18,689,725	14,987,272
Total assets		61,401,810	57,482,177
FUNDS AND LIABILITIES			
Funds			
Capital funds	18	42,712,085	42,494,903
General funds	19	(9,530,848)	(5,817,709)
Designated funds	20	10,438,960	7,299,308
Total funds		43,620,197	43,976,502
Current liabilities			
Payables	21	10,099,877	7,643,976
Estimated Service Gratuity		7,681,736	5,861,699
Total current liabilities		17,781,613	13,505,675
Total funds and liabilities		61,401,810	57,482,177

My

VICE CHANCELLOR

DATE 12 May 2023

CHAIRMAN OF COUNCIL

DATE 14.05.27

STATEMENT OF COMPREHENSIVE INCOME AND EXPENDITURE FOR THE YEAR ENDED 31 MARCH 2022

	Note	2022 '9 months'	2021
		MK'000	MK'000
Government Subvention	3	12,081,416	13,437,921
Fees		1,284,330	3,211,355
Projects / Grants and Research	4	20,276,126	20,181,369
Other income	5	875,179	1,276,528
KUHeS SBUs	5	1,078,813	859,056
Total income		35,595,864	38,966,229
Expenditure			
Teaching and Research	6	8,475,770	9,756,324
Student living & Maintenance	7	1,714,375	2,066,351
Administration	8	6,113,528	5,737,682
Transport and travelling	9	596,503	531,284
ICT Department	10	322,350	299,563
Common service / Other IGA charges	11	292,532	158,179
KUHeS SBUs Expenses	12	1,017,079	1,056,804
Project and research expenses	13	11,880,355	14,597,074
Total expenditure		30,412,492	34,203,261
•			
Surplus before Designated Funds		5,183,372	4,762,968
Designated Funds		(8,395,771)	(5,584,295)
Capital expenditure (Note 14)		(1,574,077)	(738,793)
Release from Capital Fund		1,342,871	1,370,401
Surplus/(Deficit) for the year		(3,443,605)	(189,719)

STATEMENT OF CHANGES IN FUNDS AND RESERVES

For The Year Ended 31 March 2022

	Capital fund MK'000	General funds MK'000	Designated Funds MK'000	Total MK'000
Balance at 01 July 2020	29,564,315	(12,448,781)	6,578,578	23,694,112
Capital assets procured during the period	738,792	-	-	738,792
Depreciation charge for the year	(1,370,401)	-	-	(1,370,401)
Disposal of fixed assets	(107,462)	-	-	(107,462)
Revaluation Surplus	13,650,404	-	-	13,650,405
Accumulated depreciation on disposals	19,233	-	<u>-</u>	19,233
Prior Year Adjustment	21	6,820,791	=	6,820,811
Surplus/(Deficit) for the year	-	(189,719)	-	(189,719)
Net movement	-	-	720,730	720,730
Balance at 30 June 2021	42,494,902	(5,817,709)	7,299,308	43,976,502
Balance at 1 July 2021	42,494,902	(5,817,709)	7,299,308	43,976,502
Capital assets procured during the period	1,574,078	-	-	1,574,078
Depreciation charge for the year	(1,342,871)	-	=	(1,342,871)
Revaluation Surplus / (loss)	(72,445)	-	-	(72,446)
Disposal of fixed assets	-	-	-	-
Depreciation write – off on revaluation	58,421	5	-	58,421
Prior Year Adjustment	-	(269,534)	-	(269,534)
Surplus/(Deficit) for the year	-	(3,443,605)	-	(3,443,605)
Net movement	-		3,139,652	3,139,652
Balance at 31 March 2022	42,712,085	(9,530,848)	10,438,960	43,620,197

STATEMENT OF CHANGES IN FUNDS AND RESERVES

For The Year Ended 31 March 2022

	Capital fund MK'000	General funds MK'000	Designated Funds MK'000	Total MK'000
Balance at 01 July 2020	29,564,315	(12,448,781)	6,578,578	23,694,112
Capital assets procured during the period	738,792	-	-	738,792
Depreciation charge for the year	(1,370,401)	-	-	(1,370,401)
Disposal of fixed assets	(107,462)	-	-	(107,462)
Revaluation Surplus	13,650,404	-	-	13,650,405
Accumulated depreciation on disposals	19,233	-	-	19,233
Prior Year Adjustment	21	6,820,791	-	6,820,811
Surplus/(Deficit) for the year	-	(189,719)	-	(189,719)
Net movement	-		720,730	720,730
Balance at 30 June 2021	42,494,902	(5,817,709)	7,299,308	43,976,502
Balance at 1 July 2021	42,494,902	(5,817,709)	7,299,308	43,976,502
Capital assets procured during the period	1,574,078	-	-	1,574,078
Depreciation charge for the year	(1,342,871)	-	-	(1,342,871)
Revaluation Surplus / (loss)	(72,445)	-	-	(72,446)
Disposal of fixed assets	-	-	-	-
Depreciation write – off on revaluation	58,421	-	-	58,421
Prior Year Adjustment	-	(269,534)	=	(269,534)
Surplus/(Deficit) for the year	-	(3,443,605)	-	(3,443,605)
Net movement			3,139,652	3,139,652
Balance at 31 March 2022	42,712,085	(9,530,848)	10,438,960	43,620,197

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 MARCH, 2022

	2022 '9 months'	2021
Cash flows from operating activities	MK'000	MK'000
Operating cash flows before movements in working capital	(3,443,605)	(189,719)
Movements in working capital		
Decrease /(Increase) in inventories	(125,943)	651
Decrease in receivables	(688,007)	(1,020,990)
Project funds receivables	442,586	(73,073)
Increase in payables	4,276,486	(5,639,673)
Cash (used in)/generated from operations	461,517	(6,922,804)
Cash flow from investing activities		
Purchase of property, plant and equipment	(1,574,078)	(738,792)
Net cash used in investing activities	(1,574,078)	(738,792)
Net cash flow before financing	(1,112,561)	(7,661,596)
Cash flows from financing activities		
Designated funds	3,139,652	720,730
General fund	(269,534)	6,820,791
Capital fund	1,574,078	738,792
Net cash flow from financing activities	4,444,196	8,280,313
Net increase in cash and cash equivalents	3,331,638	618,715
Cash and cash equivalents at the beginning of the financial year	7,794,019	7,175,304
Cash and cash equivalents at the end of the financial year (note 19)	11,125,657	7,794,019

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

1. PRESENTATION OF FINANCIAL STATEMENTS

The financial statements, presented in Malawi Kwacha, were prepared in accordance with the *International Financial Reporting Standards* (IFRSs). The financial statements were prepared using accounting policies, which the Kamuzu University Of Health Sciences adopted and consistently applied throughout the reporting period of nine (9) months starting from 1st July, 2021 to 31st March, 2022.

1.1. Basis of Preparation

The financial statements have been prepared on the historical cost basis except for the revaluation of certain non-current assets. Historical cost is generally based on the fair value of the consideration given in exchange for assets.

1.2. Presentation currency

The financial statements have been presented in Malawi Kwacha (MK). Figures presented in the financial statements have been rounded up to the nearest thousand.

1.3. Accounting estimates

In preparing financial statements, management make estimates, judgments and assumptions which affect amounts presented in the financial statements and other financial information. Use of available information and application of judgment are inherent in the formation of estimates. Actual results in the future could differ from these estimates which may be material to the financial statements.

2. SIGNIFICANT ACCOUNTING POLICIES

The Kamuzu University Of Health Sciences adopted the accounting policies outlined in paragraphs 2.1 to 2.11. These policies were also applied consistently during the reporting period.

2.1. Properties, Plant and Equipment (PPE)

2.1.1. Recognition and Initial measurement

The cost of an item of PPE is recognized as an asset when:

- It is probable that future economic benefits associated with the item will flow to the University; and
- The cost of the item can be measured reliably.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

Item of PPE is initially measured at cost. Costs include costs incurred initially to acquire or construct an item of PPE and costs incurred subsequently to add to, replace part of, or service it. If a replacement cost is recognized in the carrying amount of an item of property, plant and equipment, the carrying amount of the replaced part is derecognized.

PPE is carried at cost less accumulated depreciation and any impairment losses except for property and motor vehicles, which are carried at revalued amount being the fair value at the date of revaluation less any subsequent depreciation, and subsequent accumulated impairment losses.

Assets acquired under finance leases are capitalized, outstanding balances are shown as part of lease payables.

2.1.2. Subsequent expenditure

Expenditure incurred to replace a component of an item of PPE is recognized in full when it is incurred and added to the carrying amount of the asset. It will be depreciated over its expected useful economic life, which may be different from the expected life of the other components of the asset. The carrying amount of the item being replaced is derecognized when the replacement takes place.

2.1.3. Depreciation

Depreciation is recognized so as to write off the cost of valuation of assets (other than freehold land and properties under construction) less their residual values over their useful economic lives using the straight line method.

When an item of PPE is revalued, any accumulated depreciation at the date of the revaluation is restated proportionately with the change in the gross carrying amount of the asset so that the carrying amount of the asset after revaluation equals its revalued amount. The revaluation surplus in funds related to a specific item of PPE is transferred directly to general fund when the asset is de-recognized.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

SIGNIFICANT ACCOUNTING POLICIES (Continued)

The estimated economic useful lives, residual values and depreciation method are reviewed at each year-end with the effect of any changes in estimates accounted for on a prospective basis.

Categories	Average Useful lives
Land and building	40 years
Motor Vehicle	5 years
Furniture and equipment	5 years
Computers	4 years

Assets held under finance leases are depreciated over their expected useful lives on the same basis as owned assets or, where shorter, the term of the relevant lease.

The gain or loss arising from recognition of an item of PPE is included in surplus or deficit when the item is de-recognized. The gain or loss arising from de-recognition of an item of PPE is determined as the difference between the net disposal proceeds, if any, and the carrying amount of the item.

2.1.4. Impairment and Valuation

The carrying amounts of PPE are reviewed at each financial reporting date to determine whether there is any indication of impairment. If such indication exists, assets recoverable amount is estimated. In impairment loss is recognized whenever the carrying amount of an asset or its cash generating unit exceeds its recoverable amount. Impairment losses are recognized in surplus or deficit.

At each financial reporting date, carrying amounts of tangible assets are reviewed to determine whether there is any indication that those assets suffered an impaired loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognized as an expense immediately, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of this recoverable amount, so that the increased carrying amount does not exceed the carrying amount that would have been determined

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

SIGNIFICANT ACCOUNTING POLICIES (Continued)

had no impairment loss been recognized for the asset in prior years. A reversal of an impairment loss is recognized as income immediately, unless the relevant asset is carried

as a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

2.1.5. Valuation of Land and Buildings

Buildings were revalued by Chartered Surveyors from The Malawi Polytechnic as at 30 June, 2021. Land was valued by the same Chartered Surveyors as at 30 June 2018, and those values have been recognized.

2.2. Foreign currency transactions

Foreign currency transactions are translated into Malawi Kwacha at spot rate. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated to Malawi Kwacha at the foreign exchange rate ruling at that date. Foreign exchange differences arising on translation are recognized in the statement of comprehensive income. Non-monetary assets and liabilities denominated in foreign currencies that are stated at fair value are translated to Malawi Kwacha at foreign exchange rates ruling at the date that values were determined.

2.3. Income

When the outcome of transaction involving the rendering of services can be estimated reliably, revenue associated with the transaction is recognized by reference to the stage of completion of transaction at the end of the reporting period.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

SIGNIFICANT ACCOUNTING POLICIES (Continued)

The outcome of transaction can be estimated reliably when all the following conditions are satisfied:

- The amount of revenue can be measured reliably;
- It is probable that the economic benefits associated with the transaction will flow to the University;
- The stage of completion of the transaction at the end of the reporting period can be measured reliably; and
- The costs incurred for the transaction and the costs to complete the transaction can be measured reliably.

When the outcome of the transaction involving the rendering of services cannot be estimated reliably, revenue is recognized only to the extent of the expenses recognized that are recoverable.

2.3.1. Government subvention

Government subvention is recognized in the statement of comprehensive income upon receipt of fund from Central Government.

2.3.2. Government grants

Government grants are recognized when there is reasonable assurance that;

- The University will comply with the conditions attaching to them; and
- The grants will be received.

Government grants are recognized as income over the periods necessary to match them with the related costs that they are intended to compensate.

A government grant that becomes receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs is recognized as income of the period in which it becomes receivable.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

SIGNIFICANT ACCOUNTING POLICIES (Continued)

Government grants related to assets, including non-monetary grants at fair value, are presented in the statement of financial position by setting up the grant as deferred income or by deducting the grant in arriving at the carrying amount of the asset. Grants related to income are deducted from the related expense.

Repayment of a grant related to income is applied first against any unamortized deferred credit set up in respect of the grant. To the extent that the repayment exceeds any such deferred credit, or where no deferred credit exists, the repayment is recognized immediately as an expense.

Repayment of a grant related to an asset is recorded by increasing the carrying amount of the asset or reducing the deferred income balance by the amount repayable. The cumulative additional depreciation that would have been recognized to date as an expense in the absence of the grant is recognized immediately as an expense.

2.3.3. Fees and financial contributions

Fees and financial contributions are recognized in the financial statements on an accruals basis.

2.3.4. Project grants and research income

Project grants and research income are funds received for specific purposes. These are recognized as income in the period they are received in order to match them with the related costs that they are intended to compensate.

2.3.5. Interest income

Interest income represents the interest earned and accrued for the year on investments and staff loans.

2.3.6. Income generating activities

Income from income generating activities is measured at the fair value of the consideration received or receivable.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.4. Financial instruments

The University groups financial assets and financial liabilities into the following categories,

- Financial assets at fair value through profit or loss held for trading;
- Loans and receivables:
- Available for sale financial assets; and
- Financial liabilities measured at a mortised cost.

Classification depends on the purpose for which the financial instruments were obtained or incurred and takes place at initial recognition. Classification is re-assessed on an annual basis.

2.4.1. Initial recognition and measurement

Financial instruments are recognized initially when the University becomes a party to the contractual provisions of the instruments. The University classifies financial instruments or their component parts, on initial recognition as a financial asset, a financial liability or an equity instrument in accordance with the substance of the contractual arrangement.

Financial instruments are measured initially at fair value, except for equity investments for which a fair value is not determine, which are measured at cost and classified as available- for financial assets. For financial instruments which are not at fair value, through statement of comprehensive income, transaction costs are included in the initial measurement of the instrument.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.4.2. Subsequent measurement

Financial instruments at fair value through or loss are subsequently measured at fair value, with gains and losses arising from changes in fair value being included in surplus or deficit for period.

Loans and receivables are subsequently measured at amortized cost, using the effective interest method, less accumulated impairment losses.

Available-for-sale financial assets are subsequently measured at fair value. This excludes equity investments for which a fair value is not determinable, which are measured at cost less accumulated impairment losses.

Gains and losses arising from changes in fair value are recognized in other comprehensive income and accumulated in funds until the asset is disposed of or determined to be impaired. Interest on available-for-sale financial assets calculated using the effective interest method is recognized in statement of comprehensive income as part of other income. Dividends received on available-for-sale equity instruments are recognized in statement of comprehensive income as part of other income when the University's right to receive is established.

Changes in fair value of available-for-sale financial assets denominated in a foreign currency are analyzed between translation differences resulting from changes in amortized cost and other changes in the carrying amount. Translation differences on monetary items are recognized in surplus or deficit, while translation differences on non-monetary items are recognized in other comprehensive income and accumulated in funds.

Financial liabilities at amortized cost are subsequently measured at amortized cost, using the effective interest method.

2.5. Receivables

Receivables comprise of student receivables, staff receivables, prepayment, staff advances, and sundry non-trade receivables. These are measured at amortized cost. An impairment loss is recognized in statement of income, where there is objective evidence that it is impaired.

NOTES TO THE FINANCIAL STATEMENTS (*Continued*) FOR THE YEAR ENDED 31 MARCH 2022

2.0 SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.6. Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, and other short term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value. These are initially and subsequently recorded at fair value.

2.7. Inventories

Inventories are stated at the lower of cost and net realizable value. Costs, including an appropriate portion of the fixed and variable overhead expenses, are assigned to inventories by the method most appropriate to the particular class of inventory, with the majority being valued on a first-in-first-out basis. Net realizable value represents the estimated selling price for inventories less all estimated costs of completion and costs necessary to make the sale.

2.8. Provisions and contingencies

Provisions are recognized when:

- The University has a present obligation as a result of a past event;
- It is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and
- Reliable estimates can be made of the obligation.

The amount of a provision is the present value of the expenditure expected to be required to settle the obligation. Provisions are not recognized for future operating losses.

If the University has a contract that is onerous, the present obligation under the contract is recognized and measured as a provision. Contingent assets and liabilities are not recognized. Contingencies are disclosed in notes to the financial statements.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

SIGNIFICANT ACCOUNTING POLICIES (Continued)

When some or all the economic benefits required to settle a provision are expected to be recovered from a third party, a receivables recognized as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

2.9. Superannuation

The University contributes to a defined pension contribution scheme for employees. Contributions are charged to the statement of income.

3 Government Subvention

	2022	2021
	MK'000	MK'000
Annual operations	12,081,416	13,437,921
Total subvention	12,081,416	13,437,921

4 Project Grants and Research Income

	2022 MK'000	2021 MK'000
Unspent funds from previous years	5,583,989	5,486,839
Prior Year Adjustments	(14,610)	(14,548)
Grants received	13,911,565	13,484,888
Interest received	223,945	47,128
Other income	217,880	582,405
Exchange gain	353,357	594,657
Total project grants and research income	20,276,126	20,181,369

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

5 Other Income

	2022	2021
	MK'000	MK'000
Interest earned	65,811	95,528
IGA Activities	39,183	20,128
Hiring; Conferences/workshops & Vehicles	21,368	30,193
Donations & grants	8,570	175,007
Prepaid Income	19,191	18,585
Research Admin fees	471,621	740,202
Exchange gain	12,237	27,573
Sundry income	237,198	169,312
Total other income	875,179	1,276,528
KUHeS SBUs		
KUHeS Sports Complex Centre	456,599	227,205
KUHeS (BT) PVT Clinic	580,177	580,975
David Livingstone Memorial Clinic	42,037	50,876
Total	1,078,813	859,056

6. Teaching and Research

Teaching and Research	2022	2021
	MK'000	MK'000
Salaries	5,271,630	6,112,641
Tevet Levy	44,173	50,306
Clinical allowances	464,231	535,745
Perks	246,586	359,943
Gratuity	212,181	278,759
Superannuation costs	823,676	907,662
Medical expenses	103,249	124,539
Sub total	7,165,726	8,369,595
General expenses	1,100,720	
Examination expenses	59,113	73,431
Staff Uniform	2,901	- · ·
Advertising	1,637	_
Consumables/cleaning	4,679	9,991
Teaching materials	87,301	83,169
Student attachments	20,284	8,482
Conferences & workshops	50,986	43,718
Telephone	4,695	13,204
Printing & Stationery	46,260	25,489
Staff training & development	145,967	226,270
Postgraduate programmers – training	19,293	12,492
Repairs – office & other equipment	13,663	8,133
Postage/document delivery	-	373
Passages	4,983	7,266
Meeting expenses	82,306	68,470
Fuels & oils	3,583	8,718
Mileage claim	5,676	3,925
Subsistence Allowance	201,077	161,014
Finance charges	1,465	7,789
Furniture and fittings	5,592	_
Ceremonies/Graduation/Open Days	-	150
Exchange loss		19
Research & Publications	3,145	- - 102
Subscriptions	1,860	5,193
Professional Charges		1,156
Sub Total	766,466	768,452
Total	7,932,192	9,138,047

	MK'000	MK'000
Library		
Salaries	328,032	397,412
Tevet Levy	1,658	2,090
Perks	69,906	70,004
Masm/medical expenses	10,140	12,989
Superannuation costs	56,904	63,231
Sub total	466,640	545,726
General expenses		
Books & periodicals	23,606	1,400
Training & development	8,877	10,165
Hospitality	-	7
Conference & workshop	1,060	2,172
Printing & Stationery	15,222	27,240
Tools & Equipment	7,374	426
Meetings	1,868	4,024
Mileage refund	24	12
Repairs & Maintenance – Office equipment	5,758	1,722
Passages	-	99
Consumables & cleaning materials	206	-
Phone/fax/e-mail	77	137
Subsistence allowance	10,775	10,281
Professional charges	2,090	14,820
Ceremonies / Graduation/ Open Days	_	45
Subtotal	76,937	72,550
Total	543,577	618,276
Total Teaching and learning expenses	8,475,770	9,756,324

7. Student Living

	2022	2021
	MK'000	MK'000
Wages	21,256	21,716
Tevet Levy	243	258
Staff benefits	5,829	4,892
Gratuity	-	1,123
MASM/medical expenses	66,906	221,256
Superannuation	-	13,887
General expenses		
Meals & meal coupon	2,326	20,830
Phone/fax/e-mail	19,032	95,386
Student Welfare	4,063	482
Meetings	1,699	-
Student Union activities	24,090	12,834
Dispensary	426	15,333
Printing & Stationery	2,517	130
Teaching Materials	_	11,271
Examination Expenses	-	6,632
Students Attachment	6,959	30
Student Sports Expenses	4,207	-
Ceremonies/ graduation/ open days	217	1,242
Subscriptions	720	-
Electricity	209,081	328,884
Water	510,666	506,620
Repairs-buildings	170,394	183,154
Repairs – property & premises	80,465	92,187
Repairs office equipment	2,503	5,710
Mileage Refund	85	398
Cleaning services & consumables	141,460	141,866
Subsistence Allowances	126	9
Rent Expenses	3,927	186
Security services	415,840	369,765
Furniture & fittings	19,337	9,473
Tools & other Equipment	-	796
Total student living & maintenance expenses	<u>1,714,375</u>	2,066,351

8. Administration

	2022	2021
Salaries	MK'000 1,345,611	MK'000
TEVETA Levy	33,750	1,547,417
Staff benefits	247,082	40,028
Superannuation costs	224,813	241,586
Gratuity	44,179	479,585
MASM/medical expenses	60,668	78,717
General expenses	00,006	51,958
Advertising & Recruitment	21,184	25 220
Fuels and oils	22,297	35,328 45,244
Delinking Expenses	8,729	45,244
Postgraduate programmes	10,739	68,206 8.452
Conferences & workshops	43,643	8,452 71,114
Printing & Stationery	118,900	66,783
Council Expenses	56,223	502
Passage	50,225	1,659
Telephone	96,830	112,444
Repairs - office equipment	17,170	39,833
Consumables/cleaning	35,872	6,435
Meeting expenses	41,527	72,684
Postage/document delivery	218	3,725
Tools and other equipment	11,980	46,303
Covid 19 expenses	46,733	153,059
Staff training & development	32,157	31,080
Staff and students welfare	11,829	16,928
Meals and meal coupons	1,955	10,728
City and Rent Expenses	1,340	267,240
Examination expenses	24,720	10,757
Hospitality	7,263	6,871
Finance charges	42,866	26,626
PPDA Levy	1,064	
Mileage claim	4,305	4,670
Subscriptions	13,776	20,054
Subsistence allowance	232,007	254,154
Student Uniform	11,354	562
Office equipment	2,510	205
Furniture & fittings	3,997	_
Repairs & maintenance - buildings	16,168	87,839
Research & publications	1,044	180
Professional charges	101,206	129,132
Legal Charges	-	47,243
Exchange loss	1,273	837

Marketing & Publications	33,856	6,047
Provision for Doubtful Debts	-	53,156
Estimated Service Gratuity as at 31.03.2022	1,820,037	253,005
Depreciation Charge	1,236,875	1,254,047
Write Off	16,744	63,158
Bad Debts	7,035	32,828
Total administration expenses	6,113,528	5,737,682

9. Transport and Travelling

	2022	2021
	MK'000	MK'000
Wages	119,922	144,569
TEVET Levy	523	618
Staff Benefits	26,807	30,864
MASM/medical expenses	5,122	6,560
Gratuity	5,047	9,788
Superannuation costs	19,946	22,958
General expenses	3	,,,,
Mileage Claim	7,375	4,546
Fuel and oils	133,648	93,732
Subsistence allowance	71,361	56,204
Motor repairs and maintenance	129,836	119,384
Motor licensing	72,149	37,430
Repairs & Maintenance - Buildings	<u>-</u>	3,535
Consumables and cleaning vehicles	133	321
Printing & Stationery	451	161
Hiring vehicles	685	-
Postage / document delivery	_	6
Staff Uniform	1,078	530
Training & staff development	2,314	-
Phone/fax/e-mail	106	77
Total transport and traveling	596,503	531,284

10 ICT Department

	2022	2021
	MK'000	MK'000
Salaries	115,872	136,807
TEVET/Levy	1,226	1,477
Perks/Staff Benefits	12,502	11,317
Superannuation costs	23,074	27,217
Gratuity	1,895	5,642
MASM/Medical expenses	3,179	2,254
General expenses		
Telephone	131,302	97,160
Stationery	2,989	4,625
Training & staff development	-	800
Repairs - office equipment	12,670	1,691
Meetings	1,319	759
Subsistence allowance	15,464	9,785
Conference & Workshops	859	_
Subscriptions	-	30
Total for ICT Department	322,350	299,563

11 Common Service & Iga Expenses

	2022	2021
	MK'000	MK'000
Student sports expenses	4,582	700
General insurance	144,414	111,928
Fringe Benefits Tax	76,045	15,167
Staff Sports Expenses	382	-
Subscriptions	-	7,305
Ceremonies/graduation/open days	6,826	1,477
IGA expenses	60,282	21,603
Total common service and other charges	292,532	158,179

12 SBU Expenses

KUHeS Sports Complex		
Operation expenses Total Sports Complex Centre expenses	2022 MK'000 402,064 402,064	2021 MK'000 342,677 342,677
KUHeS Private Clinic		
Operational expenses Total KUHeS PVT Clinic expenses	529,282 529,282	577,519 577,519
David Livingstone Memorial Clinic (Dlmc)		
Operational expenses Total DLMC expenses	85,732 85,732	136,607 136,607
Total SBUs Expenses	<u>1,017,079</u>	1,056,804

13 Project And Research Expenses

ACEPHEM 439,228 603,384 ACT-BT Project 16,840 24,697 AESA-RISE Project 17,525 30,815 Africare - 8,390 AMARI 26,222 57,225 Antibiotic in Miscarriage Surgery 8,578 8,602 BT Clinical Research 166,165 348,046 Building Family Medicine 114,426 167,212 Building Heart & Lung Project 131,669 119,665 CDC HIV Fellowship 10,668 - CDC HIV Fellowship 15,788 270,769 CDC Partnership project 56,192 12,733 CBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams </th <th></th> <th>2022</th> <th>2021</th>		2022	2021
ACT-BT Project 16,840 24,697 AESA-RISE Project 17,525 30,815 Africare - 8,390 AMARI 26,222 57,225 Antibiotic in Miscarriage Surgery 8,578 8,602 BT Clinical Research 166,165 348,046 Building Family Medicine 114,426 167,212 Building Family Medicine 114,669 119,665 CDC CHV Fellowship 10,668 - CDC Building Family Medicine 119,665 - CDC HMCH 10,668 - CDC Patriceship project 287,369 19,560 CDC HMCHA 20,574 94,560 Centre for Reproductive Health 96,057 64,622 CHAIN 11,628 <th></th> <th>MK'000</th> <th>MK'000</th>		MK'000	MK'000
AESA-RISE Project 17,525 30,815 Africare - 8,390 AMARI 26,222 57,225 Antibiotic in Miscarriage Surgery 8,578 8,602 BT Clinical Research 166,165 348,046 Building Family Medicine 114,426 167,212 Building Heart & Lung Project 131,669 119,665 CDC HIV Fellowship 10,668 - CDC IMEM 15,788 270,769 CDC Partnership project 287,369 19,560 CDC Partnership project 287,369 19,560 CDC Partnership project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke U	ACEPHEM	439,228	603,384
Africare - 8,390 AMARI 26,222 57,225 Antibiotic in Miscarriage Surgery 8,578 8,602 BT Clinical Research 166,165 348,046 Building Family Medicine 114,426 167,212 Building Heart & Lung Project 131,669 119,665 CDC HIV Fellowship 10,668 - CDC IMEM 15,788 270,769 CDC Partnership project 56,192 12,733 CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Develop Countries Clinical Trials 478 33,529 F75 Study	ACT-BT Project	16,840	24,697
AMARI 26,222 57,225 Antibiotic in Miscarriage Surgery 8,578 8,602 BT Clinical Research 166,165 348,046 Building Family Medicine 114,426 167,212 Building Heart & Lung Project 131,669 119,665 CDC HIV Fellowship 10,668 - CDC IMEM 15,788 270,769 CDC Partnership project 56,192 12,733 CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 CON-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 2,498 Gates EED	AESA-RISE Project	17,525	30,815
Antibiotic in Miscarriage Surgery 8,578 8,602 BT Clinical Research 166,165 348,046 Building Family Medicine 114,426 167,212 Building Heart & Lung Project 131,669 119,665 CDC HIV Fellowship 10,668 - CDC IMEM 15,788 270,769 CDC Partnership project 287,369 19,560 CDC Partnership project 287,369 19,560 CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 CONT IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529	Africare	-	8,390
BT Clinical Research 166,165 348,046 Building Family Medicine 114,426 167,212 Building Heart & Lung Project 131,669 119,665 CDC HIV Fellowship 10,668 - CDC IMEM 15,788 270,769 CDC Partnership project 287,369 19,560 CDE Partnership project 287,369 19,560 CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 2,498 Gates EED	AMARI	26,222	57,225
Building Family Medicine 114,426 167,212 Building Heart & Lung Project 131,669 119,665 CDC HIV Fellowship 10,668 - CDC IMEM 15,788 270,769 CDC Partnership project 56,192 12,733 CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 2,249 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project -	Antibiotic in Miscarriage Surgery	8,578	8,602
Building Heart & Lung Project 131,669 119,665 CDC HIV Fellowship 10,668 - CDC IMEM 15,788 270,769 CDC Partnership project 56,192 12,733 CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 2 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 3	BT Clinical Research	166,165	348,046
CDC HIV Fellowship 10,668 - CDC IMEM 15,788 270,769 CDC Partnership project 56,192 12,733 CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 542 252 HIV Implementation Research Training 86,171 10	Building Family Medicine	114,426	167,212
CDC IMEM 15,788 270,769 CDC Partnership project 56,192 12,733 CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 2,498 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532	Building Heart & Lung Project	131,669	119,665
CDC Partnership project 56,192 12,733 CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532	CDC HIV Fellowship	10,668	-
CEBHA+Project 287,369 19,560 Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737	CDC IMEM	15,788	270,769
Centre for Reproductive Health 96,057 64,622 CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 737 6,428 Ilins Project 737 6,428	CDC Partnership project	56,192	12,733
CHAIN 71,628 71,741 ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593	CEBHA+Project	287,369	19,560
ELMA Anaesthesia Grant 2,514 947 COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37	Centre for Reproductive Health	96,057	64,622
COM-IDRC IMCHA 20,475 36,946 COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	CHAIN	71,628	71,741
COST Africa 1,424 479 Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	ELMA Anaesthesia Grant	2,514	947
Cryotherapy - 156 Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	COM-IDRC IMCHA	20,475	36,946
Diabetic Clinic 948 61 SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	COST Africa	1,424	479
SOAR Dreams 99 830 Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	Cryotherapy	-7	156
Duke University 191 318 EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	Diabetic Clinic	948	61
EU Beamish Project - 82 EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	SOAR Dreams	99	830
EU Develop Countries Clinical Trials 478 33,529 F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	Duke University	191	318
F75 Study - 22 Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	EU Beamish Project	-	82
Gates EED - 2,498 Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	EU Develop Countries Clinical Trials	478	33,529
Gates Malaria 650,795 489,967 Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	F75 Study	-	22
Global Health Project - 72,720 Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	Gates EED	-	2,498
Helse TB Project 451,046 394,106 HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	Gates Malaria	650,795	489,967
HIV EHPSA MSM Project 542 252 HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	Global Health Project	-	72,720
HIV Implementation Research Training 86,171 104,569 ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	Helse TB Project	451,046	394,106
ICMER 2 508,532 747,890 IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	HIV EHPSA MSM Project	542	252
IKMC Project 29,198 189,073 ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	HIV Implementation Research Training	86,171	104,569
ILINS FANTA Project 737 6,428 Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	ICMER 2	508,532	747,890
Ilins Project 186,136 111,593 Infectious Disease 45,907 37,341	IKMC Project	29,198	189,073
Infectious Disease 45,907 37,341	ILINS FANTA Project	737	6,428
	Ilins Project	186,136	111,593
Kusamala Project 12 268	Infectious Disease	45,907	37,341
	Kusamala Project	12	268

Lungwena Umoyo	_	118
MAC ENTO Studies Project	554,005	799,086
MAC Laboratory	-	80
Majete Malaria Project	204	2,426
Malaria Decision Support System	22	268,945
Malarid PMC	21,792	36,746
MARCH Study	14,189	184,856
Marternal Child Health	36,562	38,584
Mazira Project	157	197
MCDC PHD Fellowship	_	488
Mental Health Departmental Project	6,430	27,911
MIEHCAP Project	1,471	252
MORDOR Study	40,978	47,770
NAC BDS Study	-	2,966
NORHED ASCA Project	6,233	36,932
NORHED Surgery	12,115	99,020
Norway/SIDA Phase 4	,	507
Performance Based	-	1,332
Pharmacy Expansion Project	188	13,925
Premier Postgraduate	41,163	4,066
Research Ethics Committee	47,466	47,948
Research Support Centre	33,055	30,895
SACORE Grant	22,900	55,633
Scottish Collaboration	206	314
Small grants	324,636	189,640
SOAR Project	-	9,361
SPCD Project	7,424	3,562
St. Louis Nutrition	16,934	102,782
Sugarfact	450	4,043
Surg Africa	12,778	211,771
THRU Project	38,967	46,221
Traypanogen Project	21,304	23,651
United Front for Body Rights	-	23,031
Universal financial risk	-	551
Urban Malaria	_	42
CBM SENT	_	64
AEVGI	640	38,421
GAVI	203,786	377,548
Thanzi la onse	198,778	164,250
NAC I-Tech (BDSS)	170,770	117,980
· ()	-	117,700

Total Blantyre Campus	10,500,366	13,584,418
Case Control Project	83,139	
COVID 19 Self Testing Study	95,563	-
HEPU HSJP	43	-
HEPU Project	24,441	-
Football Nurse	22,568	-
Norhed Price	45,924	-
EDCTP Impala	57,259	-
Immunogenicity Project	2,922	_
Norhed II Project	77,495	-
Pericovid Project	154	-
KUHes Corruption Project	18,564	19,435
Impress Study	128,443	9,889
Bloodsafe Study	60,166	44
TFGH Covid 19 vaccination	94,621	6,422
SCATHIM	149,933	293,936
CDC Healers	419,028	286,694
Smokeless	23,508	26,708
Alert Study	51,776	48,412
CHEER	497,221	600,881
Maternal near Miss Project	35,074	169,574
Generation MW	49,026	151,609
MITS	2,278	26,399
IMPROVE 2	110,547	312,453
Drink	7,044	70,396
Rapaed	5,094	124,919
CPMZ	835	18,151
NEST	1,151,880	1,319,544
PEER Cancer	206,211	237,877
Nutritional Sub Study	133	5,370
Maldent	183,161	176,203
STHP	21	55,203
P 20	307,730	76,229
MVIP PHNG GSK	367,930	1,120,883
MAZID	1,419,960	1,398,744

Lilongwe Campus Projects Expenses

Community Based Implementation on HIV	36,421	139,571
Public Sector Investment Programme	250,344	256,301
Norhed	8,108	62,903
ELMA Funds	-	8,664
Group Antenatal Care Project	215,090	207,113
Lugina Funds	-	340
Still Birth Project	18,550	60,108
KCN Research Project	28,679	-
Hope for the Future	264	-
NEPI	-	627
APPHC Project	21,495	84,915
ENHEIT Project	57,051	20,109
SUCCEED	17,056	42,132
Melinda Gates	-	8,826
Miscellaneous Project & Research Expenses	304,982	15,439
Student Funds	421,949	105,608
Sub Total – LL Campus Projects	1,379,989	1,012,656
Total KUHeS Project and Research Expenses	11,880,355	14,597,074
J		

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

14 Property, Plant And Equipment

	Land	Work in Progress	Motor	Intangib le	Furniture, Fittings &	
	Buildings	Buildings	Vehicles	Assets	Equipment	Total
Cost	K'000	K'000	K'000	K'000	K'000	K'000
At 01 July 2020	32,036,749	401 226	1.010.524	25 200	4 451 017	20.054.400
Additions	36,344	401,236 210,574	1,919,534	27,389	4,471,215	38,856,123
Revaluation	12,381,166	210,374	11,952	-	479,923	738,793
Disposal & Donations	12,381,100		232,396		1,036,844	13,650,406
Internal Transfers	327,448	(327,448)	-	-	(107,462)	(107,462)
Depreciation before Revaluation	(5,338,534)	(327,440)	<u>(1,591,790)</u>	-	(2.712.621)	(10.742.055)
At 30 June 2021	39,443,173	<u>284,362</u>	<u>572,092</u>	27,389	(3,712,631) 2,167,887	(10,642,955)
	93,110,1170	204,502	<u>572,072</u>	<u>27,307</u>	2,107,007	42,494,905
At 01 July 2021	39,443,173	284,362	572,092	27,389	2,167,887	42,494,902
Additions	17,463	1,006,478	293,338	27,007	256,798	1,574.077
Revaluations	-		(72,445)	_		<u>(72,445)</u>
At 31 March 2022	39,460,636	1,290,840	792,985	27,389	2,424,685	43,996,537
				=-,1-0>		1012701201
Depreciation						
At 01 July 2020	4,669,377	_	1,419,681	_	3,202,732	9,291,790
Removal of Depreciation on Disposal	-	_	-	-	(19,233)	(19,233)
Charge for the year main	669,158	~	172,109	_	529,132	1,370,399
Depreciation before revaluation	(5,338,535)		(1,591,790)		(3,712,631)	(10,642,956)
At 30 June 2021	<u>-</u>				_	
		_				
At 01 July 2021	-	-	-	-	-	-
Charge for the year	775,598	-	152,322	_	414,953	1,342,873
Depreciation before revaluation			(58,421)			(58,421)
At 31 March 2022	<u>775,598</u>		<u>93,901</u>		414,953	1,284,452
Carry amount At 31 March 2022	38,685,038	<u>1,290,840</u>	699,084	27,389	2,009,732	42,712,085
At 30 June 2021	39,443,173	284,362	572,092	<u>27,389</u>	2,167,887	42,494,905

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022

14 PROPERTY, PLANT AND EQUIPMENT (Continued

The properties were revalued as at 30 June 2021 by Department of Land Economy of Malawi University of Business & Applied Sciences – MUBAS (formerly, University of Malawi - The Polytechnic), P/Bag 303, Chichiri, Blantyre 3.

Measurement of Fair Values

Land and buildings were valued as at 30 June 2018 by independent valuers, who had experience in the location and category of land and buildings. The independent valuers provide the fair values the College's Land and Buildings with sufficient regularity. Due to the varied nature of the Institutions properties, two methods are used to determine fair values namely:

- 1. The Depreciated replacement cost which is used for all properties which do not have a ready and active market such as remote and purpose built properties
- 2. The Comparative and investment method which is used for all properties that have a ready and active market such as all residential and commercial properties in the urban and trading centres.

The fair value measurement for all of the Land and buildings has been categorised as a Level 3 fair value based on the inputs to the valuation technique used.

15 Inventory

	2022	2021
	K'000	K'000
Consumables	10,400	16,762
Stationery	3,176	3,478
Projects & SBUs	145,840	13,234
Total inventories	159,416	33,474

Note briefly: Inventory relate to stores which was purchased but not yet used during the reporting period

16 Receivables

	2022	2021
	K'000	K'000
Staff advances	700,498	552,978
Inter-colleges	550	550
Student receivables	3,681,470	2,998,692
Other receivables	171,843	683,533
Prepayments	19,191	4,630
Cash Imprest	22,567	5,842
June 2020 Government Subvention	-	583,432
KUHeS (BT) PVT Clinic	297,476	248,133
KUHeS Sports Complex	172,279	86,024
David Livingstone Memorial Clinic	107,806	108,042
Project funds receivables	1,703,556	1,260,423
Projects receivables & Cash Imprests	527,417	627,501
110,000 10001.0010 00 00000	7,404,652	7,159,779

Note:

- Student Receivables are recognized net of Provision for Doubtful Debts (MWK'000 (56,510) in 2022 and MWK'000 (90,072) in 2021)
- Other Receivables are also recognized net of Provision for Doubtful Debts (MWK'000 (53,156) in 2021)

17 Cash and Cash Equivalents

	2,022 K'000	2,021 K'000
Foreign currency denominated accounts (FCDA)	234,301	433,962
Current accounts	1,618,267	1,725,355
Fixed Deposit accounts	919,805	548,294
KUHeS Sports Complex	82,745	29,358
KUHeS (BT) Pvt Clinic	92,265	30,346
David Livingstone Memorial Clinic	6,493	4,126
Projects accounts	8,189,487	5,080,671
J	11,143,363	7,852,112
KUHeS Main (Cashbook negative balances)	(12,992)	(42,086)
Projects (Cashbook negative balances)	(4,714)	(16,006)
	(17,706)	(58,093)
Cash and cash equivalents as at 31March2022	11,125,657	7,794,019

18 Capital Fund

Capital fund represents the total expenditure incurred to procure or otherwise construct all items of Plant, Property and Equipment as outlined in Note 14 above.

19 General Fund

General fund represents an accumulation of surpluses or loses over the past reported financial periods as outlined in the Statement of Changes in Funds and Reserves.

20 Funds For Specific Purposes

	2022 MK'000	2021 MK'000
A CEDITEM		MIK UUU
ACEPHEM	19,029	471
BSHIP Faculty Overhead	278	461
COM Research Account – Admin Fees	199,564	204,918
COMED Alumni Association	24	24
Dept Funds – Anaesthesia	5,196	5,042
Dept Funds – Anatomy	23,904	21,255
Dept Funds – Biochemistry	62,615	58,954
Dept Funds – Bsc Degree In Laboratory Technician	2,315	2,315
Dept Funds - Community health	1,253	1,253
Dept Funds – Haematology	1,006	1,006
Dept Funds – Histopathology	8,358	8,511
Dept Funds – IT Department	3,540	501
Dept Funds – Library	13,067	12,305
Dept Funds – Malaria Research	2,027	152
Dept Funds – Medicine	7,011	4,976
Dept Funds – Microbiology	36,192	49,561
COM Student Scholarships	48,820	43,015
Dept Funds – Paeds	10,520	9,401
Dept Funds – Physiology	6,896	6,896
Dept Funds – Physiotherapy	26,839	17,210
Dept Funds – School of Pharmacy	8,691	3,684
Burkits/AFRICARE	2,351	2,351
Dept Funds – Undergraduate Deans Office	10,038	7,419
Dept Funds Psychiatry	358	358

Funds for specific purposes before Unspent Fund for Projects	2,043,138	1,715,896
Prior Year Adjustment	(14,610)	
Other project funds for specific purposes	791,899	554,749
Departmental Funds & Other Project Balances Other project funds for engine	1,265,849	1,161,147
KUHeS Launch	6,227	
Human Subject Protection	354	-
Else Kroner Fresenius Foundation (Paeds in Mw Grant)	32,283	-
Premier Postgraduate Project	84,003	-
COMETO – Short Courses Training	200	-
Old Mutual Hostels – Rental Income (LL-KCN Database)	1,126	_
Old Mutual Hostels – Rental Income (BT Database)	9,650	-
KUHeS LL-KCN Tuition Fees Deposits	907	-
Parents/Guardians Fundraising for Needy Students	485	-
Dept Funds – MPH Programme	11,100	-
MAP Care	1,928	1,928
SEED	2,150	6,027
COVID 19 General	262,618	233,712
DIORAPHETE Grant/Building Family Medicine	-	37
Medical Council of Malawi – Index Fee	583	583
BMGF Xebomonitoring/Africa Trypanigen	2,665	2,665
Malaria Research	90,050	90,050
Welcome Trust	18,498	18,498
UMSU/Student Rentals Clearing Account	1,791	2,208
Sundry Deposits	-	800
Student Outstanding Debtors & Overpayments	5,192	6,003
Student Debtors Refunds	1,307	1,707
Resource Mobilization Overhead	-	16,085
Postgraduate Funds	15,847	
Postgraduate & Research Overhead	1,811	10,100
PHFM Faculty Overhead	14,791	23,848
Paedriatrics Fellowship MMED Programme	153,832	99,368
Kamuzu University Of Health Sciences Sports Association	169	14,471
Medicine Faculty Overhead	427	14,491
Informatics account	32,360	24,417
Inaugural Lecturer	2,353	2,353
Funeral Parlour IGA	7,711	12,029
Guest House-Clearing account	3,539	3,539
Gates Malaria Project	-	129,131

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 MARCH 2022 20. ProjectsUnspent Funds (FFSP)

	2022	2021
	MK'000	MK'000
Abortion Study	(47,551)	(47,551)
ACEPHEM	293,229	323,141
ACT – BT Project	252	16,837
ADAPT Study	(5,826)	(5,826)
AESA – RISE Project	37,108	(449)
Africare	3,939	3,939
AMARI	111,142	111,844
Antibiotic in Miscarriage Surgery (AIMS)	28,967	17,641
ARCADE Project	(79,836)	(79,836)
Bsc Int. Med, Gynae & Anaesthesia	(28,172)	(28,172)
BT Clinical Research Project	383,661	180,520
Building Family Medicine	124,337	3,972
Building heart & Lung project	(31,972)	(24,835)
Capacity Build in Research Grants	(7,061)	(7,061)
Care for Development Project	(3,049)	(3,049)
CDC HIV Fellowship	(12,842)	(2,173)
CDC IMEM	(39,914)	(24,385)
CDC Partnership	7,393	(3,397)
CDCC	3,280	3,280
CEBHA+ Project	(13,625)	(3,988)
Centre for Reproductive Health	72,446	60,856
CHAIN	30,071	56,489
ELMA Anaesthesia Grant	111,803	870
Clinical Trial Management	(61,767)	(61,767)
COM – IDRC IMCHA	103,855	114,825
COST Africa Project	75,296	76,720
COSYST	3,801	3,800
CRH Investment Account	72,778	68,168
Cryotherapy	(2,940)	(2,940)
Diabetic Clinic	(8,940)	(7,992)
SOAR DREAMS	5,918	6,017
DUKE / MOVE University	734	925
ELMA CPAP Project	(28,916)	(28,916)
EMTCT Project	64,577	64,577

EU Beanish Project	3,791	3,791
EU Develop. Countries Clinical Trials Partnership	(479,586)	(479,151)
(EDCTP)		, , , , , ,
F75 Study	1,022	1,022
Gates EED	269,951	269,951
Gates Malaria Project	186,750	333,779
Global Health	7,701	7,636
HBGDKI Project	34,281	34,281
Health Management Unit	35,869	35,869
Health Systems Strengthening Project (Queen Margaret)	(8,696)	(8,696)
Helse TB Project	(104,254)	(55,948)
HIV EHPSA MSM Project	1,718	2,225
HIV Implementation Research Training	88,449	140,506
ICMER 2	96,206	48,549
IKMC Project	96,777	45,083
ILINS Fanta Project	76,039	76,776
ILINS Project	(200,712)	(141,236)
IMMPAQKT	1,152	1,152
Infection Disease	(33,937)	50
Intermittent Preventive Therapy	195,598	195,598
Kusamala Project	4,176	4,188
WHO Life Long Project	(112)	(112)
Lungwena Umoyo project	(64)	(64)
MAC ENTO Studies	310,932	120,599
MAC Laboratory	6,379	6,370
Majete Malaria project	32,182	32,386
Malaria Decision Support System	(86,441)	(89,237)
Malarid	115,163	115,163
Malarid PMC	40,050	15,526
MARCH Study	(3,621)	5,159
Maternal Child Health	5,881	(19,758)
Mazira Project	25,535	25,691
MCDC Phd Fellowship	10,436	10,436
Mental Health Project	37,290	34,831
MIEHCAP Project	(7,984)	(6,513)
MORDOR Project	47,301	19,900
NAC BDS Study	11,348	11,348
NACCAP	75,740	75,740
Norad Program for Masters	(440)	(440)
NORHED ASCA	39,553	45,603

NORHED Surgery	(17,585)	(7,858)
Norway / SIDA Phase 4	117,977	117,977
Performance Based project	(3,869)	(3,869)
Pharmacy Extension Project	(14,366)	(14,178)
PK-PD Models Study	(271)	(271)
Premier Postgraduate	511,794	410,631
Research Ethics Committee	(54,026)	(49,916)
Research Support Centre	(10,854)	(22,523)
SACORE Grant	(119,857)	(101,346)
Scottish Collaboration	28,394	28,250
Securing Water in Rular Malawi	(26)	(26)
Small Grants Project	688,197	631,442
SOAR Project	(17,235)	(17,235)
SPCD Project	15,971	22,469
St Louis Nutrition Project	37,966	38,413
Sugarfact	2,581	3,028
Surg Africa	(1,622)	11,037
TESA Project	364	364
THRU Project	78,696	84,501
THRU / Pfizer Project	(30,780)	(30,780)
Trypanogen Project	14,040	(823)
UNC Project	(1,071)	(1,071)
Universal Financial Risk	(419)	(419)
Urban Malaria	(815)	(815)
World Children Cancer Foundation	68,031	68,031
World Diabetes Foundation	(62)	(62)
Centre for Bioethics	(9,600)	(9,600)
CBM SENT Project (P3226)	8,843	8,843
HAP	5	5
AEVGI	372	1,008
Thanzi la Onse	(34,481)	(35,746)
GAVI	109,988	138,957
NAC I – Tech (BDSS)	17,748	17,748
MVIP	1,047,794	475,765
PHNG GSK	352,064	91,295
STHP	(11,027)	(13,427)
P 20	16,605	16,616
Maldent	24,232	1,892
Nutritional Sub Study	12,573	12,704
PEER CANCER	34,896	15,556

NEST	98,932	6,966
CPMZ	(440)	391
Rapaed	(23,985)	(18,891)
Drink	(7,962)	(1,590)
IMPROVE 2	68,182	79,417
MITS	8,476	2,505
Generation Mw	32,865	28,443
Maternity near Miss	7,087	(3,876)
CHEER	91,988	95,313
Alert Study	161,601	112,328
Smokeless	25,304	9,056
CDC Healers	69,841	16,671
SCATHIM	116,914	65,550
TFGH Covid-19 Vaccination	10,943	42,271
Blood Safe Study	32,862	35,135
Impress Study	77,890	42,175
KUHeS Corruption Project	51,762	24,599
Percovid	16,343	(28)
Norhed II Project	49,281	-
Immunogenicity Project	192,546	<u></u>
EDCTP Impala Project	478,325	_
Norhed Price	24,991	-
Footbal Nurse	59,365	_
HEPU Project	19,989	_
HEPU HSJF Project	107,311	-
COVID 19 Self Testing Study	47,908	_
Case Control Project	397,579	_
Public Sector Investment Programme	702,580	952,922
Community Based Implementation on HIV	71,655	108,076
Hope for the Future	81,188	80,126
Norhed	28,183	6,450
Group Antenatal Care Project	50,258	61,459
Lugina	20,714	20,211
Still Birth Project	40,526	4,404
KCN Research Projects & Students Funds	230,056	226,625
	8,395,822	5,583,412
Total Projects Funds balances as at 31 March 2022	10,438,960	7,299,308

21. Payables

Trade Payables Other Payables Accruals Prepayments & Students Credit Balances	2022 K'000 1,169,826 1,163,496 20,806 373,544	2021 K'000 1,148,329 1,235,777 39,970 283,104
Deferred students fees Taxes – MRA Estimated Service Gratuity (Note 22) KUHeS SBUs Project Funds Payables Total	1,761,662 4,032,430 7,681,736 612,982 965,132 17,781,614	3,459,808 5,861,699 468,419 1,008,569 13,505,675

22 Contingent Liability

The Council of the former University of Malawi resolved to abolish the service gratuity to which only staff with 20 years of service and above would be entitled to receive their gratuity. Following this development, a provision amounting to **MK'000** (7,681,736) has been recognized in the financial statements while service gratuity for staff under 20 years of service amounting to **MK'000** (9,280,913) is hereby disclosed as contingent liability.

23 Subsequent Events

Subsequent to the reporting date, no events have occurred requiring adjustment to or disclosure in the financial statements.